MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    High intensity interval training improves psychomotor function in individuals with Parkinson’s disease

    J. Marusiak, B. Fisher, A. Jaskólska, K. Słotwinski, S. Budrewicz, M. Koszewicz, K. Kisiel-Sajewicz, A. Jaskólski (Wroclaw, Poland)

    Objective: The study aimed to examine the effects of high intensity interval training (HIIT) on neurological, psychological and biomechanical aspects of psychomotor behaviors in Parkinson’s…
  • 2017 International Congress

    New method to evaluate new motor skill learning

    A.P. Quixadá, V. Sotero, J.-F. Daneault, G. Diaz, Â. Torres, J.P. Vieira, M. Fonseca, P. Bonato, N. Peña, J.G. Miranda (Salvador, Brazil)

    Objective: To present a novel approach to assessing improvements in new motor skill learning. Background: Several methods have been employed over the years to try…
  • 2017 International Congress

    The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey

    H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa (Irbid, Jordan)

    Objective: The movement disorders society task force for the Middle East (MDS-Task Force for the Middle East) conducted a survey with an aim of characterizing…
  • 2017 International Congress

    Availability of anti-Parkinsonian drugs in Thailand

    K. Sakdisornchai, R. Bhidayasiri, O. Jitkritsadakul, p. panyakaew, J. Sringean (Bangkok, Thailand)

    Objective: To determine the availability of two categories of anti-PD drugs in each level of healthcare facilities and region in Thailand. Background: Anti-Parkinsonian (PD) drugs…
  • 2017 International Congress

    Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).

    C. Olanow, K. Kieburtz, N. Livnah (New York, NY, USA)

    Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…
  • 2017 International Congress

    Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease

    M. Koivu, F. Scheperjans, E. Pekkonen (Helsinki, Finland)

    Objective: To assess  the  use of the Parkinson's  Kinetigraph™ (PKG™) in evaluating the effect of  deep brain stimulation (DBS)  in patients with advanced Parkinson's disease (PD). Background: Assessment of the effect of  DBS on bradykinesia…
  • 2017 International Congress

    The landscape of interventional trials in Parkinson disease: A 10-year review of ClinicalTrials.gov between 2006 and 2016

    K. Wyant, E. Yasuda, V. Kotagal (Ann Arbor, MI, USA)

    Objective: To review the scope of interventional trials for Parkinson disease registered on clinicaltrials.gov in the past 10 years. Background: Parkinson disease (PD) is a broad chronic condition…
  • 2017 International Congress

    Gait Asymmetry and Parkinson’s Disease

    C. Ashton, L. Solis-Cohen, L. Wagenaar, R. Laracuente, E. Sorberg, V. Vanderhorst, L. Shih (Boston, MA, USA)

    Objective: To evaluate gait asymmetry using velocity-dependent gait analysis and compare to UPDRS asymmetries. Background: Motor impairment, including gait impairment, in patients with Parkinson’s disease…
  • 2017 International Congress

    Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)

    R. Postuma, J. Anang, A. Pelletier, M. Moscovich, D. Grimes, A. Borys, S. Furtado, R. Munhoz, S. Cresswell, A. Moro, D. Hobson, L. Joseph, A. Lang (Montreal, QC, Canada)

    Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…
  • 2017 International Congress

    Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study

    M. Stacy, V. Biton, J. Aldred, A. Ellenbogen, R. Rubens, N. Modi, A. Mittur, S. Khanna, S. Gupta (Durham, NC, USA)

    Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 126
  • 127
  • 128
  • 129
  • 130
  • …
  • 155
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley